Charlotte, NC – Early stage investment group Charlotte Angel Fund announced today an $81,000 investment in Camras Vision, Inc., a medical device company focused on developing a treatment for glaucoma. This investment was a part of the Company’s $600,000 Series Seed funding. This is the Fund’s fifth investment since it formed in December 2013.
Camras Vision, based in Research Triangle Park, NC, was an attractive investment due to its novel approach for treatment of moderate to severe glaucoma sufferers, and its strong management team. The Camras Shunt, which is designed for glaucoma patients who have failed pharmaceutical therapy, is less invasive and provides patients with an accurate pressure adjustment.
To date the company has been engaged in pre-clinical testing of the shunt and development of its patent portfolio. A six month animal study in expected to conclude in 2016, which will pave the way for first in-man studies.
In addition to funding from Charlotte Angel Fund, participants in Camras Vision’s Series Seed round include IMAF Coastal Plain, IMAF Sandhills, IMAF East, RTP Capital, and IMAF RTP. In addition, the company has received grant funding from the NIH and NSF.
A significant factor in the Fund’s investment selection was Camras Vision’s strong management team. The company’s Chief Scientific Officer is Dr. Lucinda Camras, who developed the Camras Shunt. CEO Ray Krauss previously served as COO of Summit Technology (developers of LASIK eye surgery technology) and Division VP of Johnson & Johnson’s Ophthalmic Division. Roberto Alfaro, President, brings operational and financial expertise to the team.
“The Camras Vision team brings passion, focus and a strong background in ophthalmic technology and business development,” stated Greg Brown, Charlotte Angel Fund’s Administrator. “We are pleased to have participated in this financing, and look forward to participating in the development of the company and this exciting technology.”